Multi-agent chemotherapy regimen

This page covers all Multi-agent chemotherapy regimen drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds.

Phase 3 pipeline (10)

• HDS vs ProMECE/CytaBOM · Gruppo Italiano Studio Linfomi · Oncology
  HDS vs ProMECE/CytaBOM are competing chemotherapy regimens designed to treat aggressive lymphomas through different combinations of cytotoxic agents.
• PACx14 · SWOG Cancer Research Network · Oncology
  PACx14 is a chemotherapy regimen combining paclitaxel, doxorubicin, and cyclophosphamide administered in a dose-dense schedule for cancer treatment.
• Induction Cycles A4-5 · Nationwide Children's Hospital · Oncology
  Induction Cycles A4-5 is a chemotherapy regimen designed to induce remission in pediatric leukemia patients through sequential administration of multiple cytotoxic agents.
• Methotrexate, Cyclophosphamide, Cytarabine, Etoposide · St. Jude Children's Research Hospital · Oncology
  This is a multi-drug chemotherapy regimen that kills rapidly dividing cancer cells through multiple mechanisms including antimetabolite activity, alkylating damage, and topoisomerase inhibition.
• PAx5/PCMx5 · SWOG Cancer Research Network · Oncology
  PAx5/PCMx5 is a chemotherapy regimen combining prednisone, doxorubicin, cyclophosphamide, and other agents designed to treat hematologic malignancies.
• Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone · St. Jude Children's Research Hospital · Oncology
  This is a multi-drug chemotherapy regimen that combines nucleoside analogs, alkylating agents, and anthracyclines to kill rapidly dividing leukemic cells through DNA damage and inhibition of DNA synthesis.
• Modified HIT-SKK Cycle B4-5 · Nationwide Children's Hospital · Oncology
  Modified HIT-SKK Cycle B4-5 is a chemotherapy regimen combining multiple cytotoxic agents designed to treat pediatric hematologic malignancies through cell cycle disruption and DNA damage.
• Course B1 +Vin · Children's Cancer Group, China · Oncology
  Course B1 + Vin is a chemotherapy combination regimen that uses vincristine (Vin) alongside other agents in Course B1 to disrupt microtubule formation and induce apoptosis in cancer cells.
• Prednisone, Dexamethasone, Vincristine, Daunorubicin · St. Jude Children's Research Hospital · Oncology
  This is a multi-drug chemotherapy regimen that combines corticosteroid immunosuppression, alkylating agents, and cytotoxic chemotherapy to treat acute leukemia by suppressing immune response and killing rapidly dividing cancer cells.
• A arm (CLAG-M) · Polish Adult Leukemia Group · Oncology
  CLAG-M is a chemotherapy regimen combining cladribine, cytarabine, and mitoxantrone designed to induce remission in acute myeloid leukemia.